Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galapagos : increases share capital through subscription right exercises

09/20/2021 | 04:01pm EDT

Mechelen, Belgium; 20 September 2021, 22.01 CET; regulated informationGalapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Galapagos issued 7,600 new ordinary shares on 20 September 2021, for a total capital increase (including issuance premium) of €151,787.50.

Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one management board member exercised 5,000 subscription rights.

In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €354,459,739.11, the total number of securities conferring voting rights amounts to 65,530,121, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants) to subscribe to not yet issued securities conferring voting rights is (i) 8,931,342 subscription rights under several outstanding employee subscription right plans, which equals 8,931,342 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.


Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

Evelyn Fox
Director Executive Communications
+31 65 3591 999

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

1         Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market



  • Q3 Share capital increase_EN

Primary Logo

Source: Galapagos NV

2021 GlobeNewswire, Inc., source Press Releases

All news about GALAPAGOS NV
10/06GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
10/06GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
10/04GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
10/04Galapagos Presents New Data from the Selection Phase 3 Program At the United European G..
10/04GALAPAGOS : Completes Patient Recruitment In Late-Stage Inflammatory Bowel Disease Study
10/04GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
10/04Galapagos Announces Completion of Patient Enrollment for Diversity Phase 3 Study with F..
09/21GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
09/21GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
09/21GALAPAGOS : Issues New Shares For Subscription Right Exercises
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Sales 2021 520 M 605 M 605 M
Net income 2021 -220 M -256 M -256 M
Net cash 2021 4 040 M 4 702 M 4 702 M
P/E ratio 2021 -15,4x
Yield 2021 -
Capitalization 2 951 M 3 434 M 3 435 M
EV / Sales 2021 -2,10x
EV / Sales 2022 -1,45x
Nbr of Employees 1 397
Free-Float 74,5%
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 10
Last Close Price 45,04 €
Average target price 56,00 €
Spread / Average Target 24,3%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj Bhikhu Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-44.04%3 434
MODERNA, INC.219.34%134 660
LONZA GROUP AG27.07%58 240
SEAGEN INC.-0.54%31 691
CELLTRION, INC.-39.28%25 332